Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Roche Initiates Phase III Trial in COVID-19 Pneumonia | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Roche Initiates Phase III Trial in COVID-19 Pneumonia

To evaluate Actemra/RoActemra plus remdesivir in hospitalized patients with severe Pneumonia.

By: Contract Pharma

Contract Pharma Staff

Roche initiated a global Phase III, randomized, double-blind study (REMDACTA) to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir, versus placebo plus remdesivir in hospitalized patients with severe COVID-19 pneumonia, in collaboration with Gilead Sciences, Inc.

The study is expected to begin enrolling in June with a target of approximately 450 patients, the trial will enroll globally, including in the United States.

In addition to REMDACTA, Roche is conducting a global randomized, double-blind, placebo-controlled Phase III trial (COVACTA, NCT04320615) to evaluate the safety and efficacy of intravenous Actemra/RoActemra plus standard of care (SOC), versus placebo plus SOC in hospitalized patients with severe COVID-19 pneumonia. In total, approximately 450 patients will be enrolled in COVACTA and Roche expects data from the study this summer. In addition, the protocol for COVACTA allows the inclusion of patients who are being treated with antivirals, including investigational antivirals. Data from the REMDACTA trial are designed to supplement the COVACTA study.

The COVACTA study is conducted in collaboration with the U.S. FDA and BARDA. Roche is also a participant in the Accelerated COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership, led by the National Institutes of Health (NIH).

Gilead’s Remdesivir was approved by the FDA under an Emergency Use Authorization for the treatment of hospitalized patients with severe COVID-19. Remdesivir is an investigational antiviral drug being studied in multiple ongoing clinical trials, and the safety and efficacy of remdesivir for the treatment of COVID-19 are not yet established.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics